First, we examined the effects of both verteporfin (VP, YAP inhibitor) and BAY11-7082 (NF-κB inhibitor) treatment on YAP expression and NF-κB activation in CARMA3-overexpressed CRC cells. This evidence concerns the gene CARD10 and colorectal carcinoma.